Cargando…
Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis
Tuberculosis (TB) claims nearly 1.5 million lives annually. Current TB treatment requires a combination of several drugs administered for at least 6 months. Mycobacterium tuberculosis (Mtb), the causative agent of TB, can persist in infected humans and animals for decades. Moreover, during infection...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449328/ https://www.ncbi.nlm.nih.gov/pubmed/36093181 http://dx.doi.org/10.3389/fcimb.2022.957287 |
_version_ | 1784784272406609920 |
---|---|
author | Glenn, Sarah M. Turapov, Obolbek Makarov, Vadim Kell, Douglas B. Mukamolova, Galina V. |
author_facet | Glenn, Sarah M. Turapov, Obolbek Makarov, Vadim Kell, Douglas B. Mukamolova, Galina V. |
author_sort | Glenn, Sarah M. |
collection | PubMed |
description | Tuberculosis (TB) claims nearly 1.5 million lives annually. Current TB treatment requires a combination of several drugs administered for at least 6 months. Mycobacterium tuberculosis (Mtb), the causative agent of TB, can persist in infected humans and animals for decades. Moreover, during infection, Mtb produces differentially culturable bacteria (DCB) that do not grow in standard media but can be resuscitated in liquid media supplemented with sterile Mtb culture filtrates or recombinant resuscitation-promoting factors (Rpfs). Here, we demonstrate that, in an intranasal murine model of TB, Mtb DCB are detectable in the lungs after 4 weeks of infection, and their loads remain largely unchanged during a further 8 weeks. Treatment of the infected mice with dimethyl fumarate (DMF), a known drug with immunomodulatory properties, for 8 weeks eliminates Mtb DCB from the lungs and spleens. Standard TB treatment consisting of rifampicin, isoniazid, and pyrazinamide for 8 weeks reduces Mtb loads by nearly four orders of magnitude but does not eradicate DCB. Nevertheless, no DCB can be detected in the lungs and spleens after 8 weeks of treatment with DMF, rifampicin, isoniazid, and pyrazinamide. Our data suggest that addition of approved anti-inflammatory drugs to standard treatment regimens may improve TB treatment and reduce treatment duration. |
format | Online Article Text |
id | pubmed-9449328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94493282022-09-08 Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis Glenn, Sarah M. Turapov, Obolbek Makarov, Vadim Kell, Douglas B. Mukamolova, Galina V. Front Cell Infect Microbiol Cellular and Infection Microbiology Tuberculosis (TB) claims nearly 1.5 million lives annually. Current TB treatment requires a combination of several drugs administered for at least 6 months. Mycobacterium tuberculosis (Mtb), the causative agent of TB, can persist in infected humans and animals for decades. Moreover, during infection, Mtb produces differentially culturable bacteria (DCB) that do not grow in standard media but can be resuscitated in liquid media supplemented with sterile Mtb culture filtrates or recombinant resuscitation-promoting factors (Rpfs). Here, we demonstrate that, in an intranasal murine model of TB, Mtb DCB are detectable in the lungs after 4 weeks of infection, and their loads remain largely unchanged during a further 8 weeks. Treatment of the infected mice with dimethyl fumarate (DMF), a known drug with immunomodulatory properties, for 8 weeks eliminates Mtb DCB from the lungs and spleens. Standard TB treatment consisting of rifampicin, isoniazid, and pyrazinamide for 8 weeks reduces Mtb loads by nearly four orders of magnitude but does not eradicate DCB. Nevertheless, no DCB can be detected in the lungs and spleens after 8 weeks of treatment with DMF, rifampicin, isoniazid, and pyrazinamide. Our data suggest that addition of approved anti-inflammatory drugs to standard treatment regimens may improve TB treatment and reduce treatment duration. Frontiers Media S.A. 2022-08-24 /pmc/articles/PMC9449328/ /pubmed/36093181 http://dx.doi.org/10.3389/fcimb.2022.957287 Text en Copyright © 2022 Glenn, Turapov, Makarov, Kell and Mukamolova https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Glenn, Sarah M. Turapov, Obolbek Makarov, Vadim Kell, Douglas B. Mukamolova, Galina V. Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis |
title | Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis |
title_full | Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis |
title_fullStr | Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis |
title_full_unstemmed | Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis |
title_short | Dimethyl fumarate eliminates differentially culturable Mycobacterium tuberculosis in an intranasal murine model of tuberculosis |
title_sort | dimethyl fumarate eliminates differentially culturable mycobacterium tuberculosis in an intranasal murine model of tuberculosis |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449328/ https://www.ncbi.nlm.nih.gov/pubmed/36093181 http://dx.doi.org/10.3389/fcimb.2022.957287 |
work_keys_str_mv | AT glennsarahm dimethylfumarateeliminatesdifferentiallyculturablemycobacteriumtuberculosisinanintranasalmurinemodeloftuberculosis AT turapovobolbek dimethylfumarateeliminatesdifferentiallyculturablemycobacteriumtuberculosisinanintranasalmurinemodeloftuberculosis AT makarovvadim dimethylfumarateeliminatesdifferentiallyculturablemycobacteriumtuberculosisinanintranasalmurinemodeloftuberculosis AT kelldouglasb dimethylfumarateeliminatesdifferentiallyculturablemycobacteriumtuberculosisinanintranasalmurinemodeloftuberculosis AT mukamolovagalinav dimethylfumarateeliminatesdifferentiallyculturablemycobacteriumtuberculosisinanintranasalmurinemodeloftuberculosis |